Anti-spasticity agents for multiple sclerosis
Anti-spasticity agents for multiple sclerosis is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
"Anti-spasticity Agents for Multiple Sclerosis." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/451024/all/Anti_spasticity_agents_for_multiple_sclerosis.
Anti-spasticity agents for multiple sclerosis. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/451024/all/Anti_spasticity_agents_for_multiple_sclerosis. Accessed March 27, 2023.
Anti-spasticity agents for multiple sclerosis. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/451024/all/Anti_spasticity_agents_for_multiple_sclerosis
Anti-spasticity Agents for Multiple Sclerosis [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 March 27]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/451024/all/Anti_spasticity_agents_for_multiple_sclerosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Anti-spasticity agents for multiple sclerosis ID - 451024 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451024/all/Anti_spasticity_agents_for_multiple_sclerosis PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -